Immunosuppressants - France

France

The Immunosuppressants market in France is expected to witness significant growth in the coming years.
According to projections, the revenue in this market is projected to reach €0.86bn by 2024.
Furthermore, it is anticipated that the market will experience a steady annual growth rate (CAGR 2024-2029) of 14.87%, leading to a market volume of €1.72bn by 2029.
When compared globally, United States is expected to generate the highest revenue in this market, reaching a staggering €32,900.00m in 2024.
France is experiencing an increasing demand for immunosuppressants due to a rise in organ transplantation procedures.

Key regions: Australia, Germany, United Kingdom, United States, France

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The market for immunosuppressants in France has been experiencing steady growth in recent years, driven by a number of factors including increasing demand for organ transplants, rising prevalence of autoimmune diseases, and expanding use of these drugs in treating cancer and other conditions.

Customer preferences: Patients in France have shown a growing preference for immunosuppressants due to their effectiveness in preventing organ rejection and managing autoimmune diseases. Additionally, the increasing use of these drugs in cancer treatment has also contributed to their popularity among patients.

Trends in the market: One of the key trends in the immunosuppressants market in France is the growing use of biologics, which offer more targeted and effective treatment options for patients. Another trend is the increasing availability of generic versions of these drugs, which has led to greater affordability and accessibility for patients.

Local special circumstances: France has a well-established healthcare system that provides universal coverage for its citizens. This has contributed to the high demand for immunosuppressants in the country, as patients are able to access these drugs without significant financial burden. Additionally, the country has a strong research and development infrastructure, which has led to the development of innovative new therapies in the field of immunosuppression.

Underlying macroeconomic factors: The French economy has been growing steadily in recent years, which has contributed to increased healthcare spending and greater investment in research and development. Additionally, the country has a large and aging population, which has led to a rising prevalence of chronic diseases and an increased need for immunosuppressants. The government has also taken steps to promote the development and use of these drugs, including providing funding for research and offering incentives for pharmaceutical companies to invest in the French market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.